Innovative Solutions Driving Better Outcomes |
Saturday, June 3
11:45am - 12:45pm | Jennifer Jackson, PhD
Director, Translational Science and Strategy Maureen Cooper
Sr. Director, Labcorp Oncology Medical Science Liaison Team Lead Mary Nesline, MS
Sr. Director, Clinical Evidence Development | - elioTM tissue complete: FDA-cleared tumor profiling kitted solution
- Minimal Residual Disease: Tissue-agnostic treatment response monitoring in patients with metastatic colorectal cancer and its prognostic value in guiding treatment decisions
- Labcorp® Plasma FocusTM: a guideline-driven liquid biopsy test that targets 33 clinically actionable or relevant genes for advanced solid tumors
- Single gene testing and comprehensive genomic profiling in community oncology practices
|
Accelerating Precision Oncology Clinical Trial Development with a Biomarker-driven Approach |
Sunday, June 4
3:45pm - 4:45pm | Jennifer Jackson, PhD
Director, Translational Science and Strategy
Taylor Jensen, PhD
Vice President, Head of Oncology Science Rami Zahr, PhD
Senior Director, Product Strategy
Sarabjot Pabla, PhD
Head of Clinical & Research Bioinformatics
Rennie Quarles
Director, Oncology Commercialization | - Leverage your retrospective samples to gain insights on biomarkers of interest and drive clinical trial protocol design
- Draw upon unmatched data insights to help expedite patient identification and enrollment to support clinical development
- Integrate white blood cell analysis – matched normal - to enhance detection and classification of cfDNA alterations
- Utilize combined genomic and immune profiling with advanced NGS technology to develop therapies targeting immune response
- Accelerate patient access to your biomarker-directed therapeutic via industry awareness and education
|
Holistic Approaches to Addressing Key Cancer Indications |
Monday, June 5
10:45am - 11:30am | | |
| | Rebecca Previs, MD
Director, Labcorp Oncology Medical Affairs | - Evolving landscape of HER2-low breast cancer: new diagnosis and treatment paradigm shift
- Real-world analysis of patients with a history of cancer undergoing germline testing for BRCA1 and BRCA2
|
| | | |
| | | |
